

Overview of Proper Treatment of Fatty Liver Disease

¹Abdullah Yahya Al Jamahir, ²Abdullah Ali Hussain Alshawaf,
³Mohammed Yahya Al Jamahir, ⁴Mohammed Abdullah Ali Qurayshah

Abstract: This article reviews our current understanding about NAFLD, with a particular focus on existing and future therapeutic options and prevention, trying to piece together our knowledge about pathogenesis to and discuss the management. Medline, and Embase, databases were searched for relevant studies discussing the treatment of fatty liver disease through, October, 2017. Eventually, NAFLD is an increasing problem around the world and with the rising prevalence and occurrence of obesity NAFLD might soon end up being an epidemic. Regardless of the positive strides made over the last several years, a lot stays to be recognized relating to the mechanism of the illness. Our insufficient understanding of the pathogenesis is a significant hurdle in the path to forming techniques for preventing and also treating the illness. For these factors, there is a pressing demand for additional study into establishing additional diagnostic devices and therapeutic methods. Up until then, education relating to lifestyle changes for at-risk populations is essential. In NAFLD, as is the case in many diseases, an ounce of prevention is worth a pound of cure.

Keywords: Nonalcoholic fatty liver disease (NAFLD), lipoprotein lipase (LPL).

1. INTRODUCTION

Nonalcoholic fatty liver disease (NAFLD) stands for a wide range of conditions specified by build-up of fat in the liver. It varies from easy hepatic steatosis with lobular inflammation (nonalcoholic steatohepatitis or NASH) to variable degrees of fibrosis, cirrhosis as well as hepatocellular cancer [1]. Nonalcoholic fatty liver disease (NAFLD) is one of the most typical source of liver illness worldwide with frequency quotes varying from 25% to 45% in a lot of researches, raising in parallel keeping that of excessive weight and also diabetes [2]. A lot of existing quotes recommend that 68% of US grownups are obese or overweight; provided this approximated frequency, in between 75 million and 100 million people in the United States likely have NAFLD [3]. As a result of the concern of illness, it is essential to determine which patients are probably to have raised morbidity and also death pertaining to NAFLD. It is neither useful neither possible to execute liver biopsies on such a great deal of patients.

There is a raising recognition of as well as interest in NAFLD due to the fact that it is taken into consideration the leading reason for unusual liver aminotransferase levels and also chronic liver condition. The occurrence of NAFLD and also NASH are rising offered the globally epidemic of obesity and also their strong organization with the metabolic syndrome (MetS). The biological systems underlying fatty liver illness incident as well as development of NASH and also its co-morbidities stay incompletely recognized. Nevertheless, there is raising acknowledgment concerning the duty of fats in advertising liver injury via lipotoxicity [3]. Fatty liver infiltration and also lipid-induced mitochondrial disorder and oxidative anxiety to the hepatocyte are thought to be significant elements behind the development of the illness from easy fatty seepage of the liver to hepatocellular damages, inflammation and also modern liver illness [4], [5]. Therapy of NASH will certainly need the decrease of insulin resistance and also obesity-associated metabolic damages via way of life treatments that generate weight loss or with pharmacotherapy with insulin sensitizers (pioglitazone) and/or turnaround of oxidative anxiety (vitamin E), every one of which have actually come along in patients with NAFLD [6].

Medical danger aspects, such as the visibility of the metabolic syndrome and also its functions, along with arising biomarkers could assist choose patients for liver biopsy and also recognize those at greatest threat of nonalcoholic steatohepatitis and advanced liver illness. Patients with NAFLD generally, and also those with nonalcoholic steatohepatitis specifically, go to the raised danger of death from liver illness (13%), and also extra typically from heart disease (25%) as well as hatred (28%) [7].

This article reviews our current understanding about NAFLD, with a particular focus on existing and future therapeutic options and prevention, trying to piece together our knowledge about pathogenesis to and discuss the management.

2. METHODOLOGY

Medline, and Embase, databases were searched for relevant studies discussing the treatment of fatty liver disease through, October, 2017. Search restriction was applied to only English language published studies with human subjects, further we scanned the references of included studies for more concerned articles.

3. DISCUSSION

• Pathogenesis:

Normal liver processing of lipid:

The liver is just one of the concept regulatory authorities of lipid in the body. Fatty acids in the liver utilized for triglyceride (TG) synthesis are offered by diet, fat or afresh synthesis from excess sugar. In the postprandial state, chylomicrons transfer nutritional fats right into the lymphatics and also ultimately the systemic flow, where they will certainly be hydrolyzed by lipoprotein lipase (LPL) or provided to the liver. Excess carbohydrates from the diet likewise advertise the afresh synthesis of free fatty acids; acetyl-coenzyme A excess stemmed from sugar is shuttled right into the lipogenesis paths in the cytoplasm and also mitochondria.

Insulin offers a regulator for this path by triggering acetyl-CoA carboxylase (ACC) through sterol regulative element-binding protein 1c (SREBP-1c) [8] and also permitting the conversion of acetyl CoA right into malonyl-CoA. Glucose itself at high levels could trigger lipogenesis by binding the carbohydrate reaction component binding protein (ChREBP) [9]. ChREBP raises afresh synthesis of FFA via the regulation of various enzymes consisting of pyruvate kinase, fatty acid synthase and also ACC. One more essential regulator of lipid in the liver, liver x receptor (LXR), was discovered in the last twenty years [10] While the systems of LXR are not completely recognized, it is clear that it is associated with a favorable comments loop with SREBP-1c [11]. Mice with kos of LXR have considerable reductions in lipogenesis, and also LXR has actually been revealed to down control several enzymes associated with afresh lipogenesis.

In the fasting state, insulin and also glucose levels drop off and lipogenesis slows down. Glucagon and also epinephrine levels raise consequently raising the task of numerous lipases consisting of hormone sensitive lipase (HSL) and also adipocyte TG lipase (ATGL) [12]. The hydrolysis of TG by these lipases produces FFA for the liver to procedure having 3 various destinies: beta-oxidation for power development, reesterification as well as storage space within hepatocytes, or refined with lipoproteins or phospholipids and also exported as cholesterol.

Metabolic changes:

The peroxisome proliferators triggered receptors (PPAR) are a team of nuclear receptors associated with guideline of fat metabolic process and storage. PPAR α is a regulatory authority of β -oxidation and PPAR γ is associated with insulin sensitivity as well as triglyceride storage space. PPAR α raises the β -oxidation, uptake and also clearance of fats [13]. Ko versions of PPAR α have actually revealed a significant progression of steatosis, linking a feasible function in the illness [14]. Researches have likewise recorded the existence of particular SNPs (Leu162Va) and also their relationship with the development of NAFLD [15], nonetheless, various other researches have actually opposed this [16]. Further studies are still needed to develop the significance of the genetic polymorphism. Fibrates serve as agonists at PPAR α and also have actually revealed some guarantee as a therapy alternative.

PPAR γ has actually additionally revealed link to NAFLD. In murine designs of the illness, PPAR γ has actually been discovered at raised levels in the livers of mice [17]. In Addition a Pro12Ala SNP in the genetics for PPAR γ has actually been revealed to be safety versus liver injury. Nevertheless, as held true for the Leu162Va SNP in PPAR α , various other researches have actually opposed this relationship consisting of a current meta-analysis by Wang et alia [18]. The impact

of SNPs in the PPAR's needs better examination in order to effectively identify their relevance in NAFLD. The thiazolidinediones (TZDs) are the pharmacologic activators of PPAR γ .

Hormone changes:

Insulin resistance, regularly discovered in those with metabolic syndrome, excessive weight and/or diabetes, is regularly taken into consideration the essential consider creating hepatic steatosis. The variety of diabetic person patients from 1988 to 2008 has actually almost tripled [19] and also the obesity rate has raised by regarding 56%; it is for that reason not unexpected that over the exact same duration the occurrence of NAFLD has actually virtually increased. While the existence of outer, and also particularly hepatic, insulin resistance in fatty liver is typically approved, there stays conflict whether the insulin resistance is triggered by NAFLD or the other way around [20].

Researches of animal versions for fatty liver have been noted to simultaneously create hepatic steatosis and also insulin resistance, recommending that steatosis is an aspect in the growth of insulin resistance. Nevertheless, mice with even more particular mutations for hepatic steatosis do not establish insulin resistance [21]. Additionally, patients with AKT2 mutations, a second carrier for insulin in glucoregulation, establish hepatic steatosis as a result of insulin resistance. Various other patients with anomalies in apoB, ATGL, or CGI58 (a protein associated with the regulation of lipolysis and also linked in Chanarin-Dorfman syndrome) create hepatic steatosis without insulin resistance [22]. The irregular organizations in between hepatic steatosis and also insulin resistance in various anomalies recommends a complicated communication in between both sensations; these monitorings have actually resulted in the theory that the existence of insulin resistance depends on the area of TG buildup.

While additional study is should identify the domino effect relationship in between insulin resistance and also hepatic steatosis, a strong agreement stays that insulin resistance is often simultaneously existing with NAFLD. The pathogenesis of fatty liver in insulin resistance is highly connected to both significant biochemical paths insulin influences in the liver. The essential consider the development of fatty buildup is that the lipogenetic path stays conscious the impacts of insulin, while the gluconeogenesis paths, which are typically hindered by insulin, come to be immune. The outcome of this procedure is hyperglycemia, which boosts the body to create even more insulin. This insulin hypersecretion promotes lipogenesis, as the SREBP-1c mediated path preserves its reaction [23].

- **Diagnosis:**

Imaging:

Ultrasonography and also CT and MRI scanning are dependable for identifying modest to extreme fatty modifications in the liver. Hepatic fat reasons raised echogenicity on ultrasound, compared to the reduced echogenicity of the spleen or kidney cortex. In noncontrast CT scans, the fatty liver is hypodense and also shows up darker compared to the spleen. Hepatic vessels give the appearance of being reasonably brighter as well as can be misinterpreted for comparison shot. No imaging technique has the ability to compare basic steatosis and NASH or suggest the stage of fibrosis [24]. The level of sensitivity and also uniqueness of ultrasonography for identifying fatty infiltration reduces as BMI rises and also hence differs from 49% to 100% and also from 75% to 95% specifically [24]. The level of sensitivity of each imaging approach raises with the level of fatty infiltration, with a minimum of 33% steatosis being ideal for discovery [24].

Liver biopsy:

The "gold requirement" for identifying NAFLD is clinico-pathological connection, with verification of steatosis by liver biopsy and also exemption of various other reasons (e.g., alcohol) medically. Nonetheless, since alcoholic liver illness and also NAFLD have comparable histologic functions, they could not be identified through liver biopsy. The cutoff limitation of alcohol consumption that compares alcoholic and also nonalcoholic fatty liver illness is unknowned, although 20 g/d for females and 30 g/d for males is frequently utilized [25]. One basic beverage generally includes 10-20 g of alcohol.

A minimum of 5%-10% steatosis by weight is taken into consideration a need for the medical diagnosis of NAFLD [25]. Steatosis is typically macrovesicular, although it might be combined with microvesicular beads, which are seen with faulty mitochondrial oxidation of free fats.

Histologic attributes applied to identify NASH from easy steatosis are questionable and also differ in the literary works. A current seminar specified NASH as area 3 predominate macrovesicular steatosis in mix with hepatocyte ballooning and also a combined inflammatory infiltrate [25], usually with particular perisinusoidal and also pericellular fibrosis.

Liver biopsy done on patients that have constantly raised liver enzyme levels and also no viral serologic markers of chronic liver illness will certainly expose NAFLD 66%-90% of the moment [26]. The favorable anticipating worth of fatty modifications on ultrasound in this setup is approximated to be 92%-96%, whereas the unfavorable anticipating worth of a regular check is approximated to be 55%-87% [27]. In spite of this, a scientific medical diagnosis of NAFLD prior to biopsy based upon serologic examination outcomes as well as searchings for from imaging researches is appropriate in just 53%-83% of situations [26]. Nevertheless, in primary care setups where NAFLD prevails, a favorable ultrasound cause organization with metabolic danger consider the lack of viral serologic proof of chronic liver illness is most likely to be appropriate for medical diagnosis.

Serologic testing:

Various other reasons for liver illness could generally be omitted with background taking, exam and also serologic screening. In the existence of raised liver aminotransaminase degrees, it might be feasible to leave out viral liver disease, hemochromatosis, autoimmune hepatitis, chronic cholestatic illness, α 1-antitrypsin shortage as well as Wilson's condition with suitable serologic screening.

- **Management:**

Prevention:

With the raising occurrence and also occurrence of NAFLD worldwide, the function of avoiding the illness has actually ended up being a hot subject. Because of the absence of understanding of the pathogenesis of the illness, the avoidance of NAFLD stays a difficult problem. General avoidance of NAFLD includes an adjustment of the danger aspects for the illness. The biggest danger manageable danger elements for NAFLD are weight, insulin resistance and also metabolic syndrome [28]. As a result, general education on way of life adjustments, such as diet and also workout, which could decrease the danger for the progression of insulin resistance, weight gain, as well as metabolic syndrome, can be viewed as the pillar for avoidance of NAFLD.

While various other treatments, such as alcohol intake as well as nutritional supplements, have actually been recommended for condition avoidance, currently none are suggested by the American Gastrointestinal Association AGA [29]. Likewise, various other treatments have actually been revealed to avoid the development of steatosis to NASH, these are explained in detail listed below. It is essential to keep in mind, that NAFLD without steatohepatitis is not a sign for therapy, nevertheless, management alternatives are routed in the direction of either those with steatohepatitis or handling the connected comorbidities existing in those with steatosis alone. Moreover, it is essential to keep in mind that making use of preventative injections, such as the hepatitis A and also B injections, is advised in patients struggling with NAFLD and also NASH, in order to avoid additional disrespect to the currently harmed liver.

Weight loss and pharmacotherapy:

The objective of therapy is to reduce the development of NAFLD and also to avoid liver-related disease and also the fatality. Nevertheless, since illness development is sluggish and also the magnitude of disease-related morbidity and also death doubts, it is vague which patients will certainly profit most from therapy. Additionally, the majority of restorative tests to this day have actually been unrestrained, short-lived and also doing not have histologic end points, which has actually resulted in restricted therapy suggestions [30].

Both weight-loss and also workout enhance insulin resistance [32] and also are advised combined with the therapy of linked metabolic irregularities. In one research, patients complying with a limited diet (25 calories [105 kJ] each kilo perfect body weight) as well as workout program over 3 months had actually lowered liver enzyme levels and also hepatic steatosis compared to control topics, although it is unidentified whether hepatic inflammation and fibrosis enhanced in the longer term. Fast weight-loss because of a really reduced power diet (500 kcal [$<$ 2090 kJ] daily) or jejunoileal bypass need to be prevented due to the threat of getting worse inflammation and also fibrosis [31]. An affordable target is the loss of 10% of body weight over 6 months [30].

Liver transplantation:

Liver transplantation could be needed if cirrhosis creates and also is made complex by liver failure or hepatocellular cancer. Presently, regarding 3% of all transplants in North America are executed due to end-stage NAFLD [33] although this figure does not consist of patients with cryptogenic cirrhosis or those averted from going through liver transplantation as a result of comorbidities associated with insulin resistance. Reoccurrence of steatosis after transplantation prevails (in 60%-100% of transplant receivers) [34] with development to steatohepatitis reported in one-third of instances [33].

Table 1. Potential treatments and their targets [35]

Obesity: Weight loss, Diet with or without exercise, Pharmacologic, Orlistat, Sibutramine, Surgical treatment of obesity
Insulin resistance: Insulin sensitizing agents, Thiazolidinediones (TZDs), Metformin, Meglitinides
Dyslipidemia: Lipid lowering agents, Statins, Fibrates, Omega-3 fatty acids
Oxidative stress: Antioxidants, Vitamin E, Other vitamins, Betaine, N-Acetyl-cysteine, Lecithin, Silymarin, Beta-carotene
Pro-inflammatory cytokines: Anti-tumor necrosis factor agents, Pentoxifylline
Bacterial overgrowth: Probiotics, VSL#3
Apoptosis: Cytoprotective agents, Ursodeoxycholic acid (UDCA), Novel treatments, ACE inhibitors/ARBs, Oligofructose, Incretin analogs

4. CONCLUSION

Eventually, NAFLD is an increasing problem around the world and with the rising prevalence and occurrence of obesity NAFLD might soon end up being an epidemic. Regardless of the positive strides made over the last several years, a lot stays to be recognized relating to the mechanism of the illness. Our insufficient understanding of the pathogenesis is a significant hurdle in the path to forming techniques for preventing and also treating the illness. For these factors, there is a pressing demand for additional study into establishing additional diagnostic devices and therapeutic methods. Up until then, education relating to lifestyle changes for at-risk populations is essential. In NAFLD, as is the case in many diseases, an ounce of prevention is worth a pound of cure.

REFERENCES

- [1] Caldwell S, Argo C. The natural history of non-alcoholic fatty liver disease. *Dig Dis*. 2010;28(1):162–8.
- [2] Day C. Genetic and environmental susceptibility to non-alcoholic fatty liver disease. *Dig Dis*. 2010;28:255–60.
- [3] Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. *Gastroenterology*. 2012;142(4):711–25
- [4] Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of Nonalcoholic Fatty Liver Disease 9 nontriglyceride fatty acid metabolites. *Hepatology*. 2010;52(2): 774–88.
- [5] Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. *Gastroenterology*. 2001;120(5):1183–92.
- [6] Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. *New Engl J Med*. 2006;355(22): 2297–307.
- [7] Feldstein AE. Novel insights into the pathophysiology of nonalcoholic fatty liver disease. *Semin Liver Dis*. 2010;30(4): 391–401
- [8] Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. *Cell*. 1997;89:331–340.
- [9] Yamashita H, Takenoshita M, Sakurai M, Bruick RK, Henzel WJ, Shillinglaw W, Arnot D, Uyeda K. A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver. *Proc Natl Acad Sci USA*. 2001;98:9116–9121.
- [10] Willy PJ, Umesono K, Ong ES, Evans RM, Heyman RA, Mangelsdorf DJ. LXR, a nuclear receptor that defines a distinct retinoid response pathway. *Genes Dev*. 1995;9:1033–1045.

- [11] Huang Y, He S, Li JZ, Seo YK, Osborne TF, Cohen JC, Hobbs HH. A feed-forward loop amplifies nutritional regulation of PNPLA3. *Proc Natl Acad Sci USA*. 2010;107:7892–7897.
- [12] Langin D. Adipose tissue lipolysis as a metabolic pathway to define pharmacological strategies against obesity and the metabolic syndrome. *Pharmacol Res*. 2006;53:482–491.
- [13] Rogue A, Renaud MP, Claude N, Guillouzo A, Spire C. Comparative gene expression profiles induced by PPAR γ and PPAR α/γ agonists in rat hepatocytes. *Toxicol Appl Pharmacol*. 2011;254:18–31.
- [14] Costet P, Legendre C, Moré J, Edgar A, Galtier P, Pineau T. Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. *J Biol Chem*. 1998;273:29577–29585.
- [15] Domenici FA, Brochado MJ, Martinelli Ade L, Zucoloto S, da Cunha SF, Vannucchi H. Peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms in nonalcoholic fatty liver disease: a study in Brazilian patients. *Gene*. 2013;529:326–331.
- [16] Dongiovanni P, Valenti L. Peroxisome proliferator-activated receptor genetic polymorphisms and nonalcoholic Fatty liver disease: any role in disease susceptibility? *PPAR Res*. 2013;2013:452061.
- [17] Chao L, Marcus-Samuels B, Mason MM, Moitra J, Vinson C, Arioglu E, Gavrilova O, Reitman ML. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. *J Clin Invest*. 2000;106:1221–1228.
- [18] Wang J, Guo X, Wu P, Song J, Ye C, Yu S, Zhang J, Dong W. Association between the Pro12Ala polymorphism of PPAR- γ gene and the non-alcoholic fatty liver disease: a meta-analysis. *Gene*. 2013;528:328–334.
- [19] Centers for Disease Control and Prevention. CDC's Diabetes Program - Data & Trends - Prevalence of Diabetes - Number (in Millions) of Civilian, Noninstitutionalized Persons with Diagnosed Diabetes, United States, 1980-2011.
- [20] Takamura T, Misu H, Ota T, Kaneko S. Fatty liver as a consequence and cause of insulin resistance: lessons from type 2 diabetic liver. *Endocr J*. 2012;59:745–763.
- [21] . Chakravarthy MV, Pan Z, Zhu Y, Tordjman K, Schneider JG, Coleman T, Turk J, Semenkovich CF. “New” hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. *Cell Metab*. 2005;1:309–322.
- [22] Greenberg AS, Kraemer FB, Soni KG, Jedrychowski MP, Yan QW, Graham CE, Bowman TA, Mansur A. Lipid droplet meets a mitochondrial protein to regulate adipocyte lipolysis. *EMBO J*. 2011;30:4337–4339.
- [23] Brown MS, Goldstein JL. Selective versus total insulin resistance: a pathogenic paradox. *Cell Metab*. 2008;7:95–96.
- [24] Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. *Gastroenterology* 2002;123:745-50.
- [25] Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. *Hepatology* 2003;37:1202-19.
- [26] Sorbi D, McGill DB, Thistle JL, Therneau TM, Henry J, Lindor KD. An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities. *Am J Gastroenterol* 2000;95:3206-10.
- [27] Joy D, Thava VR, Scott BB. Diagnosis of fatty liver disease: is biopsy necessary? *Eur J Gastroenterol Hepatol* 2003;15:539-43.
- [28] Zelber-Sagi S, Lotan R, Shlomain A, Webb M, Harrari G, Buch A, Nitzan Kaluski D, Halpern Z, Oren R. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. *J Hepatol*. 2012;56:1145–1151.
- [29] Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological

Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. *Gastroenterology*. 2012;142:1592–1609.

- [30] Angulo P. Current best treatment for non-alcoholic fatty liver disease. *Expert Opin Pharmacother* 2003;4:611-23.
- [31] Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. *J Hepatol* 1991;12:224-9.
- [32] Cox KL, Burke V, Morton AR, Beilin LJ, Puddey IB. Independent and additive effects of energy restriction and exercise on glucose and insulin concentrations in sedentary overweight men. *Am J Clin Nutr* 2004;80:308-16.
- [33] Charlton M, Kasparova P, Weston S, Lindor K, Maor-Kendler Y, Wiesner RH, et al. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. *Liver Transpl* 2001;7:608-14.
- [34] Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. *Liver Transpl* 2001;7:363-73.
- [35] Lam, Brian, and Zobair M. Younossi. "Treatment Options for Nonalcoholic Fatty Liver Disease." *Therapeutic Advances in Gastroenterology* 3.2 (2010): 121–137. PMC. Web. 26 Nov. 2017.